Home » Stocks » C4 Therapeutics

C4 Therapeutics, Inc. (CCCC)

Stock Price: $27.40 USD 0.20 (0.74%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.18B
Revenue (ttm) 30.06M
Net Income (ttm) -52.11M
Shares Out 40.67M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $27.40
Previous Close $27.20
Change ($) 0.20
Change (%) 0.74%
Day's Open 27.22
Day's Range 26.75 - 28.50
Day's Volume 438,586
52-Week Range 22.40 - 28.75

More Stats

Market Cap 1.18B
Enterprise Value 986.62M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 40.67M
Float 34.44M
EPS (basic) n/a
EPS (diluted) -1.28
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 39.18
PB Ratio 8.44
Revenue 30.06M
Operating Income n/a
Net Income -52.11M
Free Cash Flow n/a
Net Cash 191.18M
Net Cash / Share 4.45
Gross Margin 71.13%
Operating Margin n/a
Profit Margin -173.36%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth10.42%-
Gross Profit21.3819.36
Operating Income-35.45-16.39
Net Income-34.10-15.71
Shares Outstanding11.6010.91
Earnings Per Share-3.67-2.21
Operating Cash Flow55.61-16.98
Capital Expenditures-1.29-2.69
Free Cash Flow54.33-19.67
Cash & Equivalents93.1338.89
Total Debt13.7514.48
Net Cash / Debt79.3824.41
Book Value-112-79.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name C4 Therapeutics, Inc.
Country United States
Employees 88
CEO Andrew J. Hirsch

Stock Information

Ticker Symbol CCCC
Stock Exchange NASDAQ
Sector Health Technology
Industry Biotechnology
Unique Identifier NASDAQ: CCCC
IPO Date October 2, 2020


C4 Therapeutics, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.